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Abstract  (250 words) 
There are inefficiencies in current approaches to monitoring patients on antiretroviral therapy (ART) 
in sub-Saharan Africa.  Patients typically attend clinics every 1-3 months for clinical assessment, 
with clinic costs being comparable with costs of drugs themselves, CD4 counts are measured every 
6 months, yet patients are rarely switched to second-line therapies.  To ensure sustainability of 
treatment programmes a transition to more cost-effective ART deliver is needed.   In contrast to the 
CD4 count, measurement of the level of HIV RNA in plasma (“viral load”) provides a direct measure 
of current treatment effect.  Viral load informed differentiated care  is a means of tailoring care 
whereby those with suppressed viral load have less frequent clinical visits and attention is paid to 
those with unsuppressed viral load to promote adherence and timely switching to a second-line 
regimen.  The most feasible approach in many countries to measure viral load is by collecting dried 
blood spot (DBS) samples for testing in regional laboratories, although there have been concerns 
over the sensitivity/specificity of DBS to define treatment failure and the delay in receiving 
results.  We use modelling to synthesize available evidence and evaluate the cost-effectiveness of 
viral load-informed differentiated care, account for limitations of DBS.  We find that viral load-
informed differentiated care using DBS is expected to be cost-effective and is recommended as 
the strategy for patient monitoring, although further empirical evidence as the approach is rolled 
out would be of value.  We also explore the potential benefits of future availability of point-of-care 
(POC) viral load tests.  
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Introduction 
It is critical for sustainability of antiretroviral therapy (ART) programmes in sub-Saharan Africa that 
the approach to monitoring people on therapy is optimized with regard to effectiveness and cost.  
Currently, in most countries patients, are required to attend clinics every 1-3 months for clinical 
assessment, with the costs of providing for such clinic attendances – for personnel, infrastructure 
and maintenance - being comparable with costs of the antiretroviral drugs themselves (1-3).  In 
most settings, patients are monitored with CD4 count measurement every 6 months with clinical 
observation at least every 3 months, but are rarely switched to second-line regimens.   A reduction 
in visit frequency in patients who are adherent to ART and doing well would benefit programmes by 
reducing costs and patients by saving travel costs and time away from work, possibly leading to 
reduced rates of defaulting from care (4).   To achieve this it is necessary to be able to identify  
objectively who is doing well on ART.  
The biomarker which most directly measures the on-going effect of ART is the HIV ribonucleic acid 
(RNA) level in plasma (“viral load”).  If viral load is suppressed, it indicates good adherence to drug 
taking and lack of drug-resistant virus.  Experience in high income countries suggests that after 1-2 
years on ART with viral load suppression visit frequency can be reduced.  If viral load is 
unsuppressed this suggests the need for improved adherence and/or a switch in regimen.  In most 
countries in sub-Saharan Africa, measurement of viral load is not so far widely available.  
Quantification of HIV RNA requires sophisticated facilities and skilled staff and costs have been high, 
although they have decreased substantially recently (5, 6).  While modelling studies have indicated 
there is a benefit of viral load monitoring over monitoring strategies based on the CD4 count or 
clinical observation (7-16) viral load monitoring has not been found to be cost-effective (7, 10-14), 
due to the cost of viral load tests and second-line regimens.   Currently, the most feasible approach 
in most countries to begin to measure viral load is to collect samples as dried blood spots (DBS).  
DBS are stable at ambient temperature and can be prepared from capillary whole blood eliminating 
the need for phlebotomy services (15).  Using existing networks for early infant HIV diagnosis, they 
can be transported to a regional or national laboratory with results subsequently returned to the 
clinic by means such as SMS.   However, presence of cells and low sample volume in DBS specimens 
mean that sensitivity and specificity for detecting whether the level is above the 1000 cps/mL 
threshold used to define viral suppression are imperfect and it is unclear if the approach is 
adequate (5, 16-27).   Looking to the future, it is anticipated that “point-of-care” (POC) tests - i.e. 
tests that enables a decision to be made about patient management at the same visit as the sample 
is taken - may become widely available (28), and this may facilitate scale-up and result in greater 
accuracy than use of DBS. 
 
In the light of these issues, we here consider the question of how should HIV treatment 
programmes in low- income countries in sub-Saharan Africa monitor patients on ART in a way that is 
likely to lead to greatest population health gains from within limited resources available (29).  Here 
we update a model previously used to compare monitoring strategies incorporating the new lower 
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costs and the potential for viral load-informed “differentiated care” based on reducing clinic visit 
costs by reducing visit frequency among virally-suppressed individuals (30, 31).   
 
 
Methods 
 
The HIV Synthesis Transmission model is an individual-based stochastic model of heterosexual 
transmission, natural history, clinical disease, and treatment of HIV infection incorporating use of 
specific drugs, resistance mutations, and adherence, which has been described previously (8,32-36).   
 
Modelling of ART programme scenario and ART monitoring strategies  
We based our simulated population around that in Zimbabwe and the the underlying model is 
described in detail in the Supplementary Material.  We assumed that up to year 2015 a CD4 count 
monitoring strategy has been employed.  Then we considered introduction of plausible alternative 
monitoring strategies and predicted outcomes over 20 years to 2035.  The seven main monitoring 
strategies compared, which are detailed in Table 1 (together with the short-hand names we use for 
the strategies from now on), cluster into three main types : clinical observation (with or without 
targeted CD4 count or viral load testing in those with clinical disease), regular CD4 count testing, or 
regular viral load monitoring.   In the case of viral load monitoring we simulate a strategy consisting 
of off-site laboratory-based testing of DBS using the World Health Organization (WHO) 
recommended 1000 RNA cps/mL threshold.   Viral load  measured < 1000 cps/mL in the past year is 
assumed to lead to  a reduction in non-ART programme costs due to lowered frequency of clinic 
visits in people on first line ART.   Measurement of viral load > 1000 cps/mL is assumed to lead to a  
targeted adherence counselling intervention, which increases adherence in some people.   We refer 
to this strategy as viral load-informed differentiated care.  Regardless of the monitoring strategy 
used, once strategy-specific failure criteria are met we assume a  probability of switching to a 
second-line regimen of 0.5 per three months.  In practice currently switch rates are lower than this, 
even in settings with viral load monitoring in place (37-39) but we chose this higher probability in 
order to be able to discern differences in effects between strategies.  In sensitivity analyses we 
consider a situation in which switch rates are zero.  Throughout, we assume monitoring is 
performed only for people on first-line ART.     
 
We model decreased precision of DBS for measuring viral load by considering the presence of HIV 
RNA in cells and the small sample volume (5, 25, 40) such that the sensitivity and specificity of the 
measure for detecting viral load >1000 cps/mL compared with measurement on a plasma sample 
are 86% and 92%, respectively (compared with values ranging from 81%-85% sensitivity and 88%-
99% specificity in (5) for most assays); we consider other values in sensitivity analysis.  We also 
assume there is a 3 month delay in the clinician acting on the result with the patient (i.e at the next 
clinical visit, even though the turn-around time of getting the result back to the clinic is generally 
less than this).     
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Sensitivity analyses were performed to consider: possible differences in population adherence 
profile, potential future increases in sexual behaviour, changes in effectiveness of the adherence 
intervention triggered by viral load being > 1000 cps/mL, a policy of initiation of ART at diagnosis, 
that visit frequency might be reduced in those with CD4 count > 350 /mm3 in the past year, a zero 
rate of switch to second-line, differences in the baseline prevalence of HIV, differences in the 
proportion on ART, differences in the rate of ART interruption if visit frequency has been reduced 
due to viral load being < 1000 copies/mL, a higher discount rate of 5% rather than 3%, and  a 10 
year time horizon instead of 20. Additionally, we considered whether whole blood or plasma is 
used, whether the test is done in a central laboratory and incurring the 3 month delay in acting on 
the result or at POC with no delay, the threshold to define failure (200, 1000 or 5000 which is only 
assessed in the context of plasma), and the frequency of measurement (6 monthly, annually or 2 
yearly).    
 
Lastly, we focussed on the specific comparison between viral load using DBS and using a plasma-
based POC test to quantify the extent of various potential advantageous features of a POC test on 
its cost-effectiveness in relation to use of DBS.    It is important to note that we are considering 
potential features of a POC test – it is not clear that such features can be delivered, so this analysis 
is directed mainly towards developers and should not be interpreted as indicating that POC tests 
will necessarily prove to have any of these advantageous features.  This is why we chose to consider 
a plasma-based POC test, although in reality it may be more likely that a whole blood-based test is 
used in order to avoid a plasma separation step.  Further details of how all these aspects are 
modelled are provided in the Supplementary Material.   
 
Economic Analysis  
Our objective is to maximize population health - the health benefits associated with the alternative 
monitoring strategies estimated using the metric disability-adjusted life years (DALYs) averted – 
from within available resources.  A health sector perspective has therefore been adopted for the 
analysis. Direct and indirect costs incurred by the patients are excluded.  Both costs and health 
benefits were discounted to present value using a 3% per annum discount rate in our base case.   
The expected costs and health outcomes associated with each monitoring strategy can be 
compared to inform which is likely to represent best value from available resources.  The cost-
effectiveness threshold for a country represents the opportunity costs of resources required to fund 
the intervention, in terms of the health gains those resources could generate if used for alternative 
purposes in the public health care system (41).  As such, the threshold for a country is not readily 
apparent, but $500 per DALY averted is likely to be at the upper end based on the magnitude of 
benefit if resources were spent on other programmatic priorities such as eliminating coverage gaps 
for ART if these are large (42). The modelling results are intended to inform decisions in sub-
Saharan African countries classified as low and low-middle income using the World Bank country 
classifications; which have typically struggled to scale-up viral load monitoring (31).  The analyses 
may also be informative to higher income countries in the region (e.g. South Africa, Botswana) that 
have already scaled up viral load monitoring but are seeking more efficient ways to deliver ART.   
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Disability weights to calculate DALYs averted were derived from a recent comprehensive study (43).  
Unit costs (in $US at 2014 prices) are detailed in Supplementary Material.   In  brief, costs of viral 
load assays are assumed to be $22, counting all components of the cost (reagents, costs of 
equipment, human resources, buildings, etc) (details in Supplementary Material).   Since POC VL 
tests are not yet available it was not possible to know the cost so we assumed a similar cost of $22 
although it is likely that costs will be higher than this.  The cost of measuring CD4 counts is assumed 
to be $10 (44).  The current annual cost (including supply chain) of the first-line regimen of 
efavirenz, emtricitabine, tenofovir (assumed used as a fixed dose combination) is assumed to be 
$144 per person per year and second-line regimen of zidovudine, emtricitabine, ritonavir-boosted 
atazanavir $312 per person per year (44).    Annual programme costs for clinic visits (not including 
drug or viral load / CD4 count tests) are $80 per year (1,2) with an assumed reduction to $40 per 
year following measurement of viral suppression because of reduced clinical visit frequency to 6-
monthly from 1-3 monthly visits (with interim pharmacy-only visits depending on amount of drug 
that can be dispensed).   
 
 
Results 
 
The status of the simulated population in 2014 is shown in Supplementary Material (Table S1).  
Mean predicted outcomes over 20 years are shown in Table 2.  The proportion of ART-experienced 
people who have fulfilled the criteria for failure of first-line ART is Iowest with no monitoring and is 
below 15% for each of the clinical monitoring strategies.  It is highest for the CD4 count monitoring 
(WHO) strategy (41%) because the failure definition is fulfilled if the CD4 count is below pre-ART 
baseline level (which can occur due to high CD4 count variability, and particularly if ART has been 
interrupted for a period).  The proportion is intermediate for the CD4 count monitoring (< 200) 
strategy and viral load-informed differentiated care using DBS strategies (at 24% and 25%, 
respectively).    The proportion of all people on ART who have viral suppression is highest with the 
viral load-informed differentiated care using DBS strategy (86%) and lowest with no monitoring 
(76%),  with the small range of 10% reflecting the generally high levels of adherence (although we 
consider in sensitivity analyses a situation in which adherence levels are lower and the proportion 
with viral suppression is accordingly lower).  The death rate  is markedly lower for the CD4 count 
and viral load monitoring strategies than for the other strategies, and this is particularly evident in 
those among whom viral load failure has occurred.   Notably, there is also a benefit of viral load-
informed differentiated care using DBS on HIV incidence over all the other strategies.    
 
Costs and their components by monitoring strategy are given in Figure 1.  Programme costs for 
clinic visits are lowest with viral load-informed differentiated care using DBS due to the reduction in 
clinic visit frequency among virally suppressed persons.  Figure 2 shows the cost effectiveness plane, 
indicating the total DALYs averted in the population over 20 years together with the increment in 
costs (both discounted), compared with no monitoring.  Due to the higher death rate in people on 
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ART and higher incidence, the clinical monitoring strategies avert less DALYs than the viral load and 
CD4 count-based monitoring strategies.   Additional costs incurred are greatest for CD4 count 
monitoring.  Viral load-informed differentiated care using DBS averts a similar number of DALYs as 
CD4 count monitoring and is the most cost effective strategy due to the reduction in non-ART 
programme costs in people with viral suppression, with an incremental cost effectiveness ratio 
(ICER) of $326 per DALY averted.  Figure 3 depicts how the ICER  is affected by the assumed costs of 
viral load  tests and savings in clinic visit costs in people with suppressed viral load.  At our base case  
viral load test cost of $22, viral load-informed differentiated care is cost-effective only so long as 
reduced clinic visits provide at least a $30 per person per year saving offset.    
 
In Figure 4 and Supplementary Figure 1,  we consider the effect of varying  model assumptions.    
Changes in the sensitivity and specificity of viral load measurement using whole blood (as used for 
DBS) did not markedly influence the ICER, nor did the extent of the assumed effect of viral load 
measurement > 1000 cps/mL on adherence.  The ICER for viral load-informed differentiated care  
was lower when we assumed lower population adherence and when we assumed higher population 
levels of condomless sex, resulting in higher HIV incidence.  In a scenario with a switch rate of zero, 
viral load informed differentiated care was cost saving.  Confirming the results in Figure 3, if no 
reduction in visit frequency is assumed with viral load monitoring (Supplementary Figure 1(u)) then 
it is not cost-effective.   The only other scenarios in which viral load-informed differentiated care  
was not cost effective was when we considered a 10 year time horizon instead of 20 years and 
when we considered a doubling of rate of ART interruption in people with a reduced visit frequency 
due to viral load being < 1000 copies/mL (Figure 4 and Supplementary Figure 1(q and r)). 
 
In the base case we have considered there to be a switch rate of 0.5 per 3 months after the 
strategy-specific failure criteria have been met.  In practice, currently in most settings, despite CD4 
counts being measured, switching rates are much lower than this.  In Figure 5 we compared use of 
the CD4 count monitoring (WHO) strategy with a low switch rate of 0.05 per 3 months (the current 
situation in many countries) - with viral load-informed differentiated care with a switch rate of 0.5 
per 3 months.  This suggests that introduction of the viral load-informed differentiated care using 
DBS accompanied by a high switch rate would lead to a substantial improvement in DALYs averted 
with a potential reduction in cost, compared with the current situation.  In the simulated model 
population of Zimbabwe, over 20 years the CD4 count monitoring (WHO) strategy averts 0.54m 
DALYs compared to no monitoring at a cost of $500m whereas viral-load informed differentiated 
care using DBS averts 1.12m DALYs compared to no monitoring at a cost of $361m.   
 
In Figure 6 we consider only the viral load-informed differentiated care strategy and assess the 
effect of variations in various aspects; whether whole blood or plasma is used, whether the test is 
POC (central laboratory testing using whole blood is our DBS scenario), the threshold to define 
failure (200, 1000 or 5000, which is only assessed in the context of plasma), and the frequency of 
measurement (6 monthly, annually or 2 yearly).  Monitoring  6-monthly instead of annually averts 
more DALYs but does not appear cost effective at the $500 threshold (ICER=$1,234).  Less frequent 
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monitoring (e.g. every 2 years) would be cost-effective if it were to avert a similar number of DALYs 
to monitoring every year.  However, implementing differentiated care based on viral load 
monitoring as infrequently as every 2 yearly is currently untested and potential downside health 
consequences are unknown so this strategy is excluded from the comparison (i.e. it is crossed out in 
Figure 6a).  Using the 5000 cps/mL threshold also averts DALYs at a similar ICER to the 1000 cps/mL 
threshold, but with reduced total benefit.  Use of a whole blood sample (e.g. DBS) instead of a 
plasma sample is not predicted to result in a marked difference in cost incurred (assuming the same 
unit cost per test) and a modest (4%) benefit in DALYs averted.  There is a modest (6%) benefit of 
POC over laboratory monitoring in DALYs averted due to the fact that the 3 months delay is 
avoided. 
 
 
Discussion 
 
Our results suggest that viral load-informed differentiated ART care, using DBS sampling if 
necessary, is likely to be cost effective in low-income settings in sub-Saharan Africa and represents a 
sustainable model for providing ART.   That said, the level of savings resulting from reduced clinic 
visits that can be realized in practice with differentiated care are as yet not certain and require 
monitoring.  The extent of savings depends partially on the cost of viral load testing: with the fully-
loaded viral load test cost of $22 used in our base case an annual saving of at least $30 per year in 
those with viral suppression is required for viral load-informed differentiated ART care to be cost-
effective.  Given annual non-ART programme costs averaging around $80 per year (2) in the context 
of patients being seen 1-3 monthly, reduction in visit frequency to 6 monthly, and perhaps in time 
for long term suppressed patients to 9-12 monthly, should enable such savings.  There is little 
evidence that patients seen at sites with higher non-ART programme costs have better outcomes 
(2).   We estimate based upon modelling Zimbabwe over 20 years, that in contrast to the current 
situation in many countries of CD4 count monitoring with low switch rates, introduction of viral 
load-informed differentiated care would more than double the number of DALYs-averted compared 
to no monitoring (1.12m vs 0.54m) and deliver these at reduced costs ($360m vs $500m).   
 
Reduction in clinic visit frequency could also affect patients’ adherence to ART and retention in care. 
There is some evidence that a reason for patients’ defaulting from care is due to an inability to keep 
up with the intensive clinic visit schedule due to travel time and cost and loss of work time (4).  
Notably, retention in care was over 90% at four years among individuals enrolled in community ART 
clubs in Mozambique, due in part to community-based adherence support, decreased travel 
requirements, and patient preference (46,47).   We did not include in our model any such 
adherence or retention benefits associated with differentiated care.  There is also the possibility 
patients may feel less connected to care with a differentiated care model, with adverse 
consequences for adherence and retention.    
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When using the CD4 count to monitor people on ART, the WHO recommended approach has been 
to define failure by a CD4 count < 100 /mm3 or a decline from pre-ART baseline.  Our modelling 
suggests that, given the high variability in CD4 count and the fact that it is not infrequent for people 
to interrupt ART for periods of time, this latter component results in low specificity and many 
patients with viral suppression would be incorrectly categorized as failing and hence switched 
unnecessarily.  The alternative approach we evaluated, similar to that used in the DART trial (48), is 
to define failure based on a CD4 < 100 in years 1-3 on ART, and a CD4 count < 200 thereafter.  This 
approach performed well in our modelling in terms of the death rate in people on ART (as it did in 
the trial itself), although it still resulted in a lower rate of viral suppression and hence a higher HIV 
incidence than with viral load monitoring, resulting in overall poorer effectiveness.  In settings 
which continue to have CD4 count capacity but not viral load capacity, this suggests the CD4 count 
monitoring (<200) strategy should be used, until viral load-informed differentiated care is 
introduced. 
 
The requirement for frequent clinic visits is partially driven by shortages of ART supplies at the 
national level, resulting in clinic level rationing of ART quantities dispensed to patients at each visit.  
Increasing country buffer stocks, as well as improving forecasting of need, could enable longer drug 
supplies to be prescribed.  However, even if it remains not possible to prescribe more than 1-2 
months of drug, various approaches can be considered to prevent patients having to make frequent 
pharmacy-only visits to clinic (46,47,49-54).  These include community ART groups, whereby one 
member picks up drug for all the members, or patients are allowed to pick up medicines in a shop 
or other non-clinical setting  (55).   Other hurdles to overcome in adopting viral load-driven 
reductions in frequency of clinical visits include obtaining buy-in from Ministries of Health for any 
required task shifting, and provision of human resources for dedicated adherence support for 
people with high viral load.   In addition, support from professional associations of clinical, nursing 
and pharmacy staff will be important.    
 
The fact that the viral load is a direct measure of the on-going effect of treatment means it provides 
an ideal means to differentiate care provision.  However, given current wider availability of CD4 
count tests, it might be suggested that the CD4 count could be used instead.  It might be, for 
example, that visit frequency for people with a CD4 count above 350 /mm3 could be reduced.  This 
would result in a similar reduction in clinic visit costs to viral load informed differentiated care.  The 
effectiveness of such an approach is unknown, however.  It would lead to some people in whom 
adherence is low and/or resistance is present and viral load is high being asked to visit clinic less 
frequently.  It is well established that CD4 counts can remain high when virologic failure is occurring 
(56) and, likewise, that the CD4 count can remain low despite full virologic suppression.  Thus, there 
would be concern over the negative effects of such a strategy and, while we did model this as a 
potential strategy (Supplementary Figure 1(j)) it is possible that we did not fully capture the extent 
of those negative effects.   
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We have largely focussed on use of DBS rather than plasma collection as an approach.  While 
plasma samples from a venepuncture and sample separation represent an ideal sample, for 
transport over 6-24 hours this requires cold temperature and so the approach is only likely to be 
applicable in areas for which samples can reach the laboratory in that time.   
 
While we have argued that a DBS approach is feasible in most settings, this is not to say that the 
approach is working well everywhere (57).  It is important that there is investment in improvements 
to existing systems, including diagnostics laboratories and logistics of specimen distribution, and we 
have endeavoured to capture these costs as part of our overall costs of delivering viral load testing 
using DBS.  It is notable that most studies evaluating viral load using DBS compared to plasma have 
been performed in a laboratory setting using venipuncture samples and a capillary tube to fill in the 
DBS card.  Few studies are available to assess performance of DBS in the real world scenario where 
it is hot, sample transport times are long, where venipuncture is not an option, and where samples 
are from a finger prick rather than a capillary tube in order to measure a precise 100 µl whole blood 
amount per DBS, although one such study has found encouraging findings (27).   Our finding of cost 
effectiveness of viral load informed differentiated care was robust to low levels of sensitivity or 
specificity using DBS (Figure 4 and Supplementary Figure 1). 
 
We simplified consideration of types of viral load test by breaking them down according to whether 
done at POC or in a laboratory and whether the sample consisted of whole blood or plasma.  We 
recognise that this is something of an over-simplification in that, for example, measurement of viral 
load by POC testing on whole blood may not always have the same sensitivity/specificity as using 
whole blood in the form of DBS.  Improved sensitivity and specificity compared with DBS offers a 
modest but real benefit, as does the ability to measure the viral load level such that it can be acted 
on the same day, avoiding a delay until the next visit or the need to contact and recall the patient.    
Even if a POC viral load test with the desirable properties we considered does become available it is 
likely that countries would use a mix of approaches, with plasma samples, DBS and POC, depending 
on settings.  It should be noted that that cost we assumed for a POC assay of $22 was essentially 
used as a place-holder for the actual cost when this becomes known.  It is uncertain whether such 
tests will be able to be delivered at this as a fully-loaded cost which takes account of staff operator 
time, and our results should be interpreted in the light of this. 
 
If differentiated care can be implemented using viral load monitoring less frequently than every 12 
months (e.g. every 24 months),  our modelling suggests that less frequent monitoring would be 
expected to be cost-effective.  However, the health risks of differentiated care with infrequent viral 
load monitoring are not well understood and may not have been fully captured in our model.  
Further evidence on whether this approach is feasible, and the health consequences of its 
implementation, is required.  Only in highly resourced healthcare systems (with a cost-effectiveness 
threshold above $1400 per DALY averted) is more frequent monitoring (e.g. every 6 months) 
expected to be cost-effective.   
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We found little evidence of substantial benefits associated with moving from a cut-off to define 
treatment failure of viral load counts > 1000 cps/mL towards either a lower or a higher cut-off.   A 
cut-off of 200 results in more DALYs being averted – due to identifying people with virologic failure 
earlier - but relies on a plasma-based test (and phlebotomy to achieve sufficient sample volume) 
and is not cost-effective at the $500 cost-effectiveness threshold.    
 
Given the role of viral load testing for enabling reduced visit frequency it should have a role also in 
people on second-line regimens.  When evaluating our monitoring strategies we assumed that CD4 
count / viral load tests would only be done in patients on first-line, so we may have understated the 
benefits of viral load-informed differentiated care. 
 
We considered whether our base case results would still hold with various alterations in 
assumptions and settings.  In a scenario in which the pattern of adherence was generally poorer 
than in our base case (leading to 68% of people on ART with viral suppression compared with 82%) 
viral load-informed differentiated care remained cost-effective.  Likewise in a scenario with high 
incidence rate, and scenarios with different HIV prevalence and ART coverage, suggesting our 
findings should hold quite broadly in various settings in the region.    
 
Randomized trials have been performed to compare outcomes from CD4 count and viral load 
monitoring and these have not identified significant differences in outcome.  Such trials have been 
characterised by relatively short follow-up and low implementation of switching to second-line 
therapy (58-64) leading to low power to detect differences.    
 
We focussed on monitoring for adults.  In children and, more likely, adolescents levels of adherence 
may be lower than in adults.  We did find that our main findings hold in populations with tendency 
for lesser adherence.  However, there may be greater reluctance to reduce visit frequency as 
children are growing up and constantly facing new challenges and situations.  Likewise, in women in 
the year or so post-partum there may be reluctance to reduce visit frequency.   We also 
considerered whether 6-monthly monitoring would be cost-effective for populations with poorer 
adherence profile (Supplementary Figure 1t) but this was not the case.  Other limitations of this 
work include the fact that we considered a hypothetical cohort with simulated outcomes, and 
future trends are uncertain, particularly in sexual behaviour, levels of male circumcision and 
adherence to ART.  Further, we assume continuation of HIV testing and ART availability at current 
trends.  The profile of new POC VL tests is also as yet uncertain as is their cost.  However, new 
diagnostic technologies, including POC viral load testing and beyond, have great potential to 
enhance delivery of HIV care.  We have investigated uncertainty through a series of one-way and 
multi-way sensitivity analyses and recognize there are other approaches such as probabilistic 
sensitivity analysis and approximate Bayesian computation that we intend to pursue in further 
work. 
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This work provides insights into how to deliver ART monitoring so that it is both effective and cost-
effective.  As well as providing some specific guidance to programmes it highlights the need to 
research this area further, to enable us to continue to understand the attributes of programmes 
and to determine how maximum health gains can be realized by patients from within the 
constrained resources available.  We find that evidence is sufficient to recommend viral-load 
differentiated care using DBS but that further empirical confirmation as the approach is rolled out 
would be valuable. 
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Table 1.  Description of the seven main monitoring strategies modelled.  The column heading is the 
short name given to the strategy.   
 
 
No 
monitoring 
Clinical 
monitoring 
Clinical 
monitoring VL 
confirmation 
Clinical 
monitoring 
CD4 count 
confirmation 
CD4 count 
monitoring 
(WHO)   
CD4 count 
monitoring  
(< 200) 
Viral load-
informed 
differentiated 
care, using 
DBS 
What the 
monitoring 
strategy 
entails (for 
people on 
first-line ART) 
-- Check on 
presence of 
symptoms 
every 3m. 
Check on 
presence of 
symptoms 
every 3m 
Measure viral 
load if WHO 4 
condition 
diagnosed or 
2 WHO 3 
conditions 
diagnosed in 
1 year. 
Check on 
presence of 
symptoms 
every 3m 
Measure CD4 
count if WHO 
4 condition 
diagnosed or 
2 WHO 3 
conditions 
diagnosed in 
1 year. 
6 m CD4 
count.  If 
failure 
criteria 
appear to be 
met, re-
measure to 
confirm 
(confirmatory 
CD4 count). 
12 m CD4 
count.  If 
failure criteria 
appear to be 
met, re-
measure to 
confirm 
(confirmatory 
CD4 count). 
 VL measure 
using DBS  at 
6m, 12m and 
every 12m 
thereafter. If 
VL > 1000 
then give 
adherence 
intervention 
and re-
measure VL 3 
m later 
(confirmatory 
VL measure).  
No CD4 count 
measurments. 
 
Failure 
criteria 
-- WHO 4 
condition 
diagnosed 
or 2 WHO 3 
conditions 
diagnosed in 
1 year. 
VL > 1000 
cps/mL 
CD4 count 
<250 /mm
3
. 
CD4 count < 
pre-ART 
baseline or 
CD4 count < 
100 /mm
3
 in 
confirmatory 
CD4 count 
CD4 count < 
200 after > 3 
years on ART.  
CD4 < 100 
/mm
3 
after > 1  
year on ART in 
confirmatory 
CD4 count) 
VL >1000 
cps/mL in 
confirmatory 
VL measure. 
Reduction in 
clinical visit 
frequency 
(and hence 
reduction in 
non-ART 
programme 
cost)* 
No No No No No No Yes, when 
most recent 
viral load  < 
1000 cps/mL, 
measured in 
past year. 
* We assume 3 monthly clinical visits for all strategies except under viral load-informed differentiated care when most 
recent viral load  < 1000 cps/mL, measured in past year.  More frequent clinical visits than 3 monthly are not modelled 
as the model advances in 3 month periods;  cps = copies;  VL = viral load; WHO 4 = WHO stage 4 condition; ART = 
antiretroviral therapy; 3m = 3 monthly, etc.    
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Table 2.   Outcomes over 20 years 2015-2035 in people with HIV (age 15-65) according to monitoring 
strategy.  For each model run for each strategy, the outcome of interest (as listed in the first column) is 
output for each 3 month period between 2015-2035.  Over 500 model runs are done for each strategy, then 
means are taken over 3 month periods and model runs.    
 
 
No 
monitoring 
Clinical 
monitoring 
Clinical 
monitoring 
VL 
confirmation 
Clinical 
monitoring 
CD4 count 
confirmation 
CD4 count 
monitoring 
(WHO)   
CD4 count 
monitoring  
(< 200) 
Viral load-
informed 
differentiated 
care  using 
DBS 
Percent of ART experienced people 
who have fulfilled criterion for 
failure of first-line ART  
7% 14% 10% 13% 41% 26% 27% 
Percent of ART-experienced people 
who have started second-line ART  
3% 13% 10% 13% 38% 24% 25% 
Percent of people on ART who 
have (true) viral load < 1000 
cps/mL (mean; over 20 year time 
horizon) 
76% 79% 78% 79% 85% 82% 86% 
Death rate (per 100 person years) 
amongst people on ART 
4.43 3.63 4.06 3.67 3.02 3.07 3.18 
Death rate (per 100 person-years) 
amongst people with HIV 
5.45 4.91 5.2 4.93 4.36 4.43 4.47 
Death rate (per 100 person-years) 
in whole adult population 
1.69 1.63 1.66 1.63 1.56 1.58 1.57 
Death rate (per 100 person years) 
amongst people on ART who have 
virologically failed 1st line 
(regardless of whether monitoring 
strategy has detected it) 
9.94 7.5 8.66 7.62 5.53 5.79 5.85 
Incidence of HIV (per 100 person 
years) 
0.84 0.81 0.83 0.81 0.76 0.79 0.73 
 
cps = copies; ART = antiretroviral therapy;  
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Figure 4.   Incremental cost-effectiveness ratio (ICER) for viral load informed differentiated care using DBS 
(compared with next less effective strategy on the efficiency frontier) according to changes in assumptions.  
In each case, except where indicated (^),viral load informed differentiated care is the strategy with the lowest 
net monetary burden at the $500 threshold.  See also corresponding cost effectiveness planes in 
Supplementary Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+ base case: sensitivity 86% and specificity 92% * clinical monitoring with CD4 count confirmation is cost-effective; ** 
such that proportion with viral suppression with no monitoring/no second-line ART  is 68% compared with 76% in base 
case and HIV incidence is 0.96 / 100 person years compared with 0.84 in base case; *** such that HIV incidence is 1.46 / 
100 person years compared with 0.84 in base case; ^ no monitoring is the most cost effective strategy; based on 200 
model runs per strategy for each of (a)-(s).   
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Figure  6.  Cost-effectiveness planes showing the effect of viral load measurement frequency, format and threshold, 
all in  the context of viral load-informed differentiated care.  In (a), 12-monthly viral load monitoring is compared to 6 
monthly (n.b. 2 yearly monitoring is excluded from the cost-effectiveness frontier due to unproven ability to base 
differentiated care on a 2 yearly value; however, if less frequent monitoring could be implemented without adverse 
health outcomes this would be cost-effective).  In (b), laboratory whole blood corresponds to DBS.   In (c), alternative 
thresholds to define failure (viral load cps/mL>200, >100 and >5000) are compared in the context of 12-monthly 
laboratory monitoring using plasma. 
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